Home Banner

The only FDA-approved systemic therapy for TGCT, also known as PVNS or GCT-TS1,2

Less Tumor.

38% overall response rate (ORR) at week 25 per RECIST (n = 23 of 61; 95% CI, 27%-50%)1

More MOVEMENT.

Significant improvement in mean change from baseline in range of motion (ROM) at week 25 with TURALIO (n = 45) vs placebo (n = 43;
P = 0.004).1,2 Of 120 total patients, results were excluded for 32 with missing data.1
Person depicted is not an actual patient.

TGCT Treatment Centers Locate healthcare professionals certified to prescribe TURALIO 
and other centers that may treat TGCT.

FIND TGCT TREATMENT
CENTERS NOW

A category 1 recommendation indicates that based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

The NCCN recommends that prior to the initiation of treatment, all patients should be evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma.

In a clinical trial of 120 patients with advanced TGCT for whom surgery was not recommended, patients were randomized to placebo (n = 59) or TURALIO (n = 61) 1000 mg daily for 2 weeks followed by 400 mg twice daily. The efficacy outcomes measured at week 25 were ORR per RECIST v1.1, ORR per Tumor Volume Score (TVS), and mean change from baseline in ROM of the affected joint. The FDA-approved dose is 400 mg orally twice daily.1

Indication and Usage

TURALIO® (pexidartinib) is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

Please click here for full Prescribing Information, including Boxed WARNING, and click here for Medication Guide.

In a clinical trial of 120 patients with advanced TGCT for whom surgery was not recommended, patients were randomized to placebo (n = 59) or TURALIO (n = 61) 1000 mg daily for 2 weeks followed by 400 mg twice daily. The efficacy outcomes measured at week 25 were ORR per RECIST v1.1, ORR per Tumor Volume Score (TVS), and mean change from baseline in ROM of the affected joint. The FDA-approved dose is 400 mg orally twice daily.1

GCT-TS, giant cell tumor of the tendon sheath; PVNS, pigmented villonodular synovitis; RECIST, Response Evaluation Criteria In Solid Tumors; TGCT, tenosynovial giant cell tumor.

Interested in TURALIO?
Get more information and resources about TURALIO: sign up for email updates and request a representative.